Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lesma, Elena ^a   Chiaramonte, Eloisa ^a   Ancona, Silvia ^a   Orpianesi, Emanuela ^a   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ALPHA SMOOTH MUSCLE ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN S6; RAPAMYCIN; RAS PROTEIN; TRANSCRIPTION FACTOR SNAIL; TUBERIN; ANTIIDIOTYPIC ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; IN VIVO STUDY; LUNG NODULE; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; MOUSE; MULTIPLE PULMONARY NODULES; NONHUMAN; PARAAORTIC LYMPH NODE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY;

GASTROPODA; MUS MUSCULUS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84933060264     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/315240     Document Type: Article

References (45)

1. R. N. Jorissen, F.Walker, N. Pouliot, T. P. J. Garrett, C.W.Ward, and A. W. Burgess, "Epidermal growth factor receptor:mechanisms of activation and signalling, " Experimental Cell Research, vol. 284, no. 1, pp. 31-53, 2003.
2. X. Lu and Y. Kang, "Epidermal growth factor signalling and bone metastasis, " British Journal of Cancer, vol. 102, no. 3, pp. 457-461, 2010.
3. S. R. Johnson and A. E. Tattersfield, "Lymphangioleiomyomatosis, " Seminars in Respiratory and Critical Care Medicine, vol. 23, no. 2, pp. 85-92, 2002.
4. K. Matsui, K. Takeda, Z. X. Yu et al., "Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunohistochemical study, " The American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 3 I, pp. 1002-1009, 2000.
5. D. M. Crooks, G. Pacheco-Rodriguez, R. M. DeCastro et al., "Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 50, pp. 17462-17467, 2004.
6. S. C. Juvet, F. X. McCormack, D. J. Kwiatkowski, and G. P. Downey, "Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans, " The American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 4, pp. 398-408, 2007.
7. J. J. Yu, V. A. Robb, T. A. Morrison et al., "Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2635-2640, 2009.
8. J. Yu and E. P. Henske, "MTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of prometastatic factors in LAM pathogenesis, " Lymphatic Research and Biology, vol. 8, no. 1, pp. 43-49, 2010.
9. K. Seyama, T. Kumasaka, M. Kurihara, K. Mitani, and T. Sato, "Lymphangioleiomyomatosis: a disease involving the lymphatic system, " Lymphatic Research and Biology, vol. 8, no. 1, pp. 21-31, 2010.
10. A. R. Tee, D. C. Fingar, B. D. Manning, D. J. Kwiatkowski, L. C. Cantley, and J. Blenis, "Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13571-13576, 2002.
11. G.D. Strizheva, T.Carsillo, W.D.Kruger, E. J. Sullivan, J.H. Ryu, and E. P.Henske, "The spectrumofmutations inTSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis, " American Journal of Respiratory and Critical CareMedicine, vol. 163, no. 1, pp. 253-258, 2001.
12. F. X. McCormack, Y. Inoue, J. Moss et al., "Efficacy and safety of sirolimus in lymphangioleiomyomatosis, " The New England Journal of Medicine, vol. 364, no. 17, pp. 1595-1606, 2011.
13. J. J. Bissler, J. C. Kingswood, E. Radzikowska et al., "Everolimus for angiomyolipoma associatedwith tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial, " The Lancet, vol. 381, no. 9869, pp. 817-824, 2013.
14. E. Lesma, S. M. Sirchia, S. Ancona et al., "The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells, " The American Journal of Pathology, vol. 174, no. 6, pp. 2150-2159, 2009.
15. E. Lesma, S.Ancona, S. M. Sirchia et al., "TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival, " Journal of Cellular and MolecularMedicine, vol. 18, no. 5, pp. 766-779, 2014.
16. E. Lesma, V. Grande, S. Ancona, S. Carelli, A. M. Di Giulio, and A. Gorio, "Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSCand LAM, " PLoSONE, vol. 3, no. 10, Article ID e3558, 2008.
17. S. Carelli, E. Lesma, S. Paratore et al., "Survivin expression in tuberous sclerosis complex cells, " Molecular Medicine, vol. 13, no. 3-4, pp. 166-177, 2007.
18. D. C. Fingar and J. Blenis, "Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression, " Oncogene, vol. 23, no. 18, pp. 3151-3171, 2004.
19. W. E. Parker, K. A. Orlova, G. G. Heuer et al., "Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex, " The American Journal of Pathology, vol. 178, no. 1, pp. 296-305, 2011.
20. E. Lesma, E.Chiaramonte, E. Isaia et al., "Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice, " The American Journal of Pathology, vol. 181, no. 3, pp. 947-960, 2012.
21. E. Lesma, V. Grande, S. Carelli et al., "Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor, " The American Journal of Pathology, vol. 167, no. 4, pp. 1093-1103, 2005.
22. S. S.N. Lam, A. S. C.Mak, J.W. P. Yam, A. N. Y. Cheung, H. Y. S. Ngan, and A. S. T. Wong, "Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells, " Molecular Therapy, vol. 22, no. 4, pp. 743-751, 2014.
23. T. Kumasaka, K. Seyama, K. Mitani et al., "Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis, " American Journal of Surgical Pathology, vol. 28, no. 8, pp. 1007-1016, 2004.
24. N.Moghal and P.W. Sternberg, "Multiple positive and negative regulators of signaling by the EGF-receptor, " CurrentOpinion in Cell Biology, vol. 11, no. 2, pp. 190-196, 1999.
25. A. Markovic and C. H. Chung, "Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma, " Expert ReviewofAnticancerTherapy, vol. 12, no. 9, pp. 1149-1159, 2012.
26. F. R. Hirsch, P. A. Jänne, W. E. Eberhardt et al., "Epidermal growth factor receptor inhibition in lung cancer: status 2012, " Journal of Thoracic Oncology, vol. 8, no. 3, pp. 373-384, 2013.
27. C. Li, X. Zhou, Y. Sun et al., "Faslodex inhibits estradiolinduced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis, " The American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 1, pp. 135-142, 2013.
28. E. Lesma, E. Chiaramonte, S. Ancona, A. M. di Giulio, and A. Gorio, "LAM/TSC cell migration to uterus in an experimental model of lymphangioleiomyomatosis. Regulation by antiepidermal growth factor receptor antibody and rapamycin, " Journal of Cytology & Histology, vol. S4, article 007, 2014.
29. J. J. Bissler, F. X. McCormack, L. R. Young et al., "Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis, " The New England Journal of Medicine, vol. 358, no. 2, pp. 140-151, 2008.
30. F. X.McCormack, W. D. Travis, T. V. Colby, E. P. Henske, and J. Moss, "Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm, " The American Journal of RespiratoryandCritical CareMedicine, vol. 186, no. 12, pp. 1210-1212, 2012.
31. R. Kalluri and R. A. Weinberg, "The basics of epithelialmesenchymal transition, " Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
32. X. Gu, J. J. Yu, D. Ilter, N. Blenis, E. P. Henske, and J. Blenis, "Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis, " Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 110, no. 37, pp. 14960-14965, 2013.
33. S. Shin, C. A. Dimitri, S.-O. Yoon, W. Dowdle, and J. Blenis, "ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events, " Molecular Cell, vol. 38, no. 1, pp. 114-127, 2010.
34. A. Clapéron, M. Mergey, T. H. Nguyen Ho-Bouldoires et al., "EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition, " Journal of Hepatology, vol. 61, no. 2, pp. 325-332, 2014.
35. A. Misra, C. Pandey, S. K. Sze, and T.Thanabalu, "Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT), " PLoS ONE, vol. 7, no. 11, Article ID e49766, 2012.
36. P. Gulhati, K. A. Bowen, J. Liu et al., "mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways, " Cancer Research, vol. 71, no. 9, pp. 3246-3256, 2011.
37. S. Lamouille and R. Derynck, "Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway, " The Journal of Cell Biology, vol. 178, no. 3, pp. 437-451, 2007.
38. J. J. Wallin, J. Guan, K. A. Edgar et al., "Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes, " PLoS ONE, vol. 7, no. 5, Article ID e36402, 2012.
39. I. Mikaelian, M. Malek, R. Gadet et al., "Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism, " Cancer Research, vol. 73, no. 22, pp. 6621-6631, 2013.
40. E.A.Barnes, H. L. Kenerson, X. Jiang, and R. S. Yeung, "Tuberin regulates E-cadherin localization: implications in epithelialmesenchymal transition, " American Journal of Pathology, vol. 177, no. 4, pp. 1765-1778, 2010.
41. D. Marino, Y. Angehrn, S. Klein et al., "Activation of the epidermal growth factor receptor promotes lymphangiogenesis in the skin, " Journal of Dermatological Science, vol. 71, no. 3, pp. 184-194, 2013.
42. A. Alitalo and M. Detmar, "Interaction of tumor cells and lymphatic vessels in cancer progression, " Oncogene, vol. 31, no. 42, pp. 4499-4508, 2012.
43. J. R.Woodburn, "The epidermal growth factor receptor and its inhibition in cancer therapy, " Pharmacology and Therapeutics, vol. 82, no. 2-3, pp. 241-250, 1999.
44. T. Kumasaka, K. Seyama, K.Mitani et al., "Lymphangiogenesis-mediated sheddinq of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis, " The American Journal of Surgical Pathology, vol. 29, no. 10, pp. 1356-1366, 2005.
45. E. A. Gonchorova, D. A. Gonchorov, and M. Fehrenbach, "Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphnagioleiomyomatosis (LAM), " Science Translational Medicine, vol. 4, no. 154, 2012.